ECSP088683A - Metodos para preparar alcoholes sulfonamida sustituidos e intermediarios de estos - Google Patents

Metodos para preparar alcoholes sulfonamida sustituidos e intermediarios de estos

Info

Publication number
ECSP088683A
ECSP088683A EC2008008683A ECSP088683A ECSP088683A EC SP088683 A ECSP088683 A EC SP088683A EC 2008008683 A EC2008008683 A EC 2008008683A EC SP088683 A ECSP088683 A EC SP088683A EC SP088683 A ECSP088683 A EC SP088683A
Authority
EC
Ecuador
Prior art keywords
methods
substituted
sulfonamide
alcohol
prepare substituted
Prior art date
Application number
EC2008008683A
Other languages
English (en)
Inventor
Panolil Raveendranath
Jianxin Ren
Mousumi Ghosh
Arkadiy Rubezhov
Anita W Chan
Joseph Zeldis
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088683A publication Critical patent/ECSP088683A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan procedimientos para preparar aminoalcoholes o sales de los mismos y compuestos de alcohol sulfonamida sustituido; de manera deseable, los compuestos de alcohol sulfonamida sustituido son compuestos de alcohol heterocíclico sulfonamida trifluoroalquilo sustituidos o compuestos de alcohol fenil sulfonamida trifluoroalquilo sustituidos
EC2008008683A 2006-02-17 2008-08-15 Metodos para preparar alcoholes sulfonamida sustituidos e intermediarios de estos ECSP088683A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77445306P 2006-02-17 2006-02-17

Publications (1)

Publication Number Publication Date
ECSP088683A true ECSP088683A (es) 2008-09-29

Family

ID=38180433

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008683A ECSP088683A (es) 2006-02-17 2008-08-15 Metodos para preparar alcoholes sulfonamida sustituidos e intermediarios de estos

Country Status (18)

Country Link
US (1) US7687666B2 (es)
EP (1) EP1984321A1 (es)
JP (1) JP2009528281A (es)
KR (1) KR20080093126A (es)
CN (1) CN101415670A (es)
AR (1) AR059518A1 (es)
AU (1) AU2007217965A1 (es)
BR (1) BRPI0707741A2 (es)
CA (1) CA2641013A1 (es)
CR (1) CR10156A (es)
EC (1) ECSP088683A (es)
GT (1) GT200800155A (es)
IL (1) IL192931A0 (es)
NO (1) NO20083491L (es)
PE (1) PE20080169A1 (es)
RU (1) RU2008129797A (es)
TW (1) TW200736195A (es)
WO (1) WO2007098029A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471099C (en) * 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
KR20060002908A (ko) * 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
AR059517A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
TW200911778A (en) * 2007-07-16 2009-03-16 Wyeth Corp Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides
JP2010533723A (ja) * 2007-07-16 2010-10-28 ワイス・エルエルシー βアミロイド生成の阻害剤
PA8789801A1 (es) * 2007-07-16 2009-02-09 Wyeth Corp Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
TW200934482A (en) * 2008-01-11 2009-08-16 Wyeth Corp Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as β -amyloid inhibitors
WO2009137657A1 (en) * 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) * 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
KR102870868B1 (ko) 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
CN119679936A (zh) 2019-06-24 2025-03-25 诺华股份有限公司 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1294380B (de) * 1955-07-21 1969-05-08 E H Karl Dr Dr Verfahren zur Reduktion von organischen Verbindungen an den C=O-Bindungen mit Metallalkylen als Reduktionsmittel
KR100266467B1 (ko) 1995-09-27 2000-10-02 우에노 도시오 설폰아미드 유도체
JPH09241262A (ja) 1996-03-08 1997-09-16 Kao Corp ３−オキサ−２，７−ジアザビシクロ〔３．３．０〕オクタン誘導体
US5962231A (en) 1997-09-30 1999-10-05 Incyte Pharmaceuticals, Inc. Human glutathione-S-transferase
CA2395558C (en) 1997-11-12 2007-07-17 Bayer Aktiengesellschaft Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
WO2001047929A1 (de) 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Triazolotriazinone und ihre verwendung
MXPA02006240A (es) 1999-12-24 2003-01-28 Bayer Ag Nuevas imidazo[1,3,5,) triazinonas y su uso.
JP2004517892A (ja) 2000-12-13 2004-06-17 ワイス β−アミロイド産生の複素環スルホンアミド阻害剤
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
BR0214863A (pt) 2001-12-11 2004-12-14 Wyeth Corp Processo para a sìntese de beta-aminoálcoois quiralmente puros
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
KR20050010882A (ko) 2002-06-11 2005-01-28 와이어쓰 베타 아밀로이드 생산의 치환 페닐술폰아미드 저해제
WO2004078731A1 (en) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Quinoline-carboxylic acids and the derivatives thereof, a focused library
KR20060002908A (ko) 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
DE602005016775D1 (de) 2004-01-16 2009-11-05 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion

Also Published As

Publication number Publication date
CR10156A (es) 2008-10-03
AU2007217965A1 (en) 2007-08-30
IL192931A0 (en) 2009-02-11
BRPI0707741A2 (pt) 2011-05-10
RU2008129797A (ru) 2010-03-27
GT200800155A (es) 2009-02-20
TW200736195A (en) 2007-10-01
WO2007098029A1 (en) 2007-08-30
JP2009528281A (ja) 2009-08-06
US20070197830A1 (en) 2007-08-23
US7687666B2 (en) 2010-03-30
KR20080093126A (ko) 2008-10-20
EP1984321A1 (en) 2008-10-29
CA2641013A1 (en) 2007-08-30
NO20083491L (no) 2008-09-05
PE20080169A1 (es) 2008-04-11
AR059518A1 (es) 2008-04-09
CN101415670A (zh) 2009-04-22

Similar Documents

Publication Publication Date Title
ECSP088683A (es) Metodos para preparar alcoholes sulfonamida sustituidos e intermediarios de estos
DOP2015000014A (es) Derivados de azaadamantano y metodos de uso de los mismos
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
NI201100108A (es) Nuevas pirazol - 4 - n - alcoxicarboxamidas como microbicidas.
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
CU23778B7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CR11370A (es) Inhibidores de quinasas simil polo
CR11241A (es) Compuestos de pirazol y su uso como inhibidores de raf
CU23751B7 (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
CR11433A (es) Inhibidores de quinasa c-fms
UY30327A1 (es) Nuevos compuestos ii
TW200732295A (en) Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
CL2008001562A1 (es) Proceso para la preparacion de compuestos de aminodiol protegidos con oxazolina; los compuestos intermediarios considerados; utiles como intermediarios en la preparacion de florfenicol.
UY29337A1 (es) N-aminometilensulfonamidas sustituidas, su preparación y su uso como medicamentos.
UA106880C2 (uk) Нові гербіциди
CU20110101A7 (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6
CL2009001235A1 (es) Compuestos derivados 4-(3-alquilsulfinilbenzoil)pirazoles, composiciones herbicidas que los contine, procedimiento para reprimir plantas indeseadas, uso dichos compuestos y compuestos intermediarios.
CU20080169A7 (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos.
DOP2011000053A (es) Agentes antifungicos
UY30801A1 (es) Compuestos calciliticos
UY28856A1 (es) Nuevos imidazoles
CL2008002058A1 (es) Metodo para la preparacion de trifluoralquil-fenil-sulfonamidas y de sulfonamidas heterociclicas usando n-trifluoroacteilmorfolina; su metodo de preparacion y su uso.
UY29804A1 (es) Quinolinas de alquilnitrilo
UY28992A1 (es) Procedimiento para carbonilar derivados de fenilalquilo con monnxido de carbono.-
CL2008002059A1 (es) Método de preparación de sulfonamidas heterocíclicas; los compuestos intermediarios usados en el método descrito; y los métodos de preparación de dichos intermediarios.